Himalaya Nutravedics IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Return Estimator (GMP*)
Financial Analysis
| Metric | 31 Mar 2024 | 31 Mar 2025 | 31 Mar 2026 |
|---|---|---|---|
| Revenue | 14.43 | 21.00 | 43.12 |
| Profit (PAT) | 0.43 | 2.23 | 7.39 |
| Total Assets | 6.09 | 10.82 | 24.42 |
Promoters: Rohit Asawa, Divya Asawa, Chanda Asawa, Rama Raju Penmatsa
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 60,00,000 | 95.14% |
| Promoter Holding Post Issue | 60,00,000 | 68.13% |
Strengths & Risks
- Solid profit margin — 17.2%.
- Strong return on equity — 64%.
- Low leverage — debt/equity of 0.31.
- Backed by anchor investors — Rs 8 crore committed pre-issue.
Risk signals for Himalaya Nutravedics will appear here as subscription, valuation and GMP data arrive. Always read the company-specific risk factors in the RHP before you apply.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Incorporated in June 2022, Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. The Company manufactures a diversified portfolio comprising classical (Shastric) Ayurvedic formulations, proprietary Ayurvedic formulations and nutraceutical supplements. Its products are available in multiple dosage forms, including soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. The products cater to therapeutic and wellness areas such as gut health, cardiac and metabolic wellness, diabetes management, pain management, immunity, women’s wellness and general wellness. Himalaya Nutravedics operates through a hybrid business model comprising its own branded products and third-party contract manufacturing. Under its own-brand business, the Company develops, manufactures and markets Ayurvedic and nutraceutical products, while its third-party manufacturing business provides formulation, manufacturing, packaging and dispatch services based on client specifications. As of March 31, 2026, its own-brand business contributed approximately ₹2,202.54 lakh, representing about 51.14% of total revenue. The Company operates an integrated manufacturing facility in Hyderabad, Telangana, where formulation, production, quality control, packaging and finished-goods release are carried out internally. The facility is compliant with WHO-GMP standards and holds registrations and licences from AYUSH and FSSAI, along with certifications including ISO 9001:2015, ISO 22000:2018, HACCP, HALAL and KOSHER. As of July 31, 2026, the Company had 86 full-time employees across marketing, factory, finance, quality, compliance and administration functions. Competitive Strengths - Geographic expansion across India. - Long-standing supplier and customer relationships. - Integrated multi-dosage manufacturing capabilities. - Doctor acceptance supported by product performance. - Broad therapeutic coverage across Ayurvedic and nutraceutical segments
| Purpose | Amount (Cr) |
|---|---|
| Funding Working Capital Requirements | 13.75 |
| Business Development and Digital Marketing Activities | 7.50 |
| General Corporate Purposes | - |
Resources & Documents
Plot No. 101/A, Phase-III Industrial Development Park Cherlapally, Hindustan Cables Ltd, Uppal Hyderabad Telangana
Himalaya Nutravedics has set a price band of Rs 100–Rs 106 per share for an issue size of Rs 25 crore. The SME issue is scheduled to open for subscription on September 22, 2026 — 4 days from now.
Incorporated in June 2022, Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. The Company manufactures a diversified portfolio comprising classical (Shastric) Ayurvedic formulations, proprietary Ayurvedic formulations and nutraceutical supplements.
The issue is promoted by Rohit Asawa, Divya Asawa, Chanda Asawa, Rama Raju Penmatsa with Nirbhay Capital Services Pvt.Ltd. acting as lead manager. Anchor investors have committed Rs 8 crore ahead of the public issue — about 30% of the total issue size. Anchor allocation was completed on September 21, 2026. Net proceeds will primarily be used towards Funding Working Capital Requirements (Rs 14 crore) and Business Development and Digital Marketing Activities (Rs 8 crore).
At the upper end of the price band, the issue is priced at a post-issue P/E of 12.63x. On fundamentals, the company is posting a profit margin of 17.2%, return on equity of 63.9% in its most recent reported period.
All figures below — GMP history, subscription tiers, financials and peers — are aggregated from public disclosures. Always apply through your own broker after reading the RHP.
Himalaya Nutravedics IPO GMP — What It Means
No active grey market premium has been recorded for Himalaya Nutravedics IPO yet. GMP is an unofficial, dealer-quoted indicator of expected listing-day demand — not a guaranteed listing price — and it can change quickly once bidding opens.
See the full Himalaya Nutravedics GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!